Prenetics Global (PRE) investor relations material

Company overview and business model

• Focuses on consumer health and longevity, leveraging science-backed products, global brand partnerships, and AI-driven operations.

• Operates primarily through two brands: IM8 (subscription-based supplements) and CircleDNA (genetic testing).

• IM8 targets daily performance and longevity, with products manufactured in FDA-registered US facilities and certified for quality.

• Strategic transformation included divesting non-core assets to focus on IM8, supported by high-profile athlete and wellness ambassador partnerships.

• IM8 employs a direct-to-consumer subscription model, expanding globally and supported by a $1B marketing facility from General Catalyst.

Financial performance and metrics

• FY2025 revenue: IM8 $60.1M (63% gross margin), CircleDNA $12.9M (85% gross margin), Europa (divested) $19.3M (~1% gross margin).

• Recent divestitures generated significant non-dilutive capital: ACT Genomics (up to $72M), Europa 3PL ($13M in stock), Insighta ($70M cash).

• Pro forma financials reflect a simpler structure post-divestitures, with improved focus on core consumer health operations.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling shareholders; may receive up to $42.5M if all Exchange Warrants are exercised for cash.

• Capital allocation is focused on supporting IM8 growth, product innovation, and strategic opportunities; digital assets fully divested in 2026 for $41.3M.

• Board authorized a $40M share repurchase program in March 2026.